Financial Performance - The company reported record quarterly net sales of 436.7millionforthesecondquarteroffiscalyear2023,a39315.3 million in the same quarter of the prior year[95]. - The company experienced a 39% increase in net sales for the six months ended December 31, 2022, totaling 842.6millioncomparedto608.0 million in the same period of the previous year[100]. - Sales in the automotive market reached 200.0millioninthesecondquarter,up44139.0 million in the same quarter of fiscal year 2022, driven by program ramp-ups and new product launches[100]. - Sales to customers in the medical market had a double-digit increase in both the second quarter and year-to-date period of fiscal year 2023 compared to the prior fiscal year[104]. - Sales to customers in the industrial market increased by 27% in the second quarter of fiscal year 2023 compared to the same period in fiscal year 2022[104]. - The impact of foreign currency fluctuations was an unfavorable 5% on net sales in the current quarter compared to the same period of fiscal year 2022[100]. Profitability and Margins - The gross profit margin improved to 7.8% in the second quarter of fiscal year 2023, compared to 6.6% in the same quarter of the previous year, reflecting a 64% increase in gross profit[100]. - Gross profit as a percentage of net sales improved in the second quarter and first half of fiscal year 2023 compared to the same periods in fiscal year 2022[102]. - Selling and administrative expenses increased in absolute dollars but declined as a percentage of net sales in the second quarter and first half of fiscal year 2023 compared to the same periods in fiscal year 2022[103]. Balance Sheet and Liquidity - The company maintained a strong balance sheet with a current ratio of 2.0 and a debt-to-equity ratio of 0.6, with shareholders' equity at 481millionasofDecember31,2022[97].−Thecurrentratioimprovedto2.0atDecember31,2022,upfrom1.9atJune30,2022[108].−Openordersincreasedby351,037 million compared to 771millionintheprioryear,indicatingstrongdemandandagrowingbacklog[100].−Openordersincreasedby3593.0 million primarily for working capital and capital expenditures supporting expansions[107]. - The company had 264.3millioninborrowingsundertheprimarycreditfacilityatDecember31,2022,comparedto171.4 million at June 30, 2022[121]. - The company sold 225.1millionofaccountsreceivablewithoutrecourseinthesixmonthsendedDecember31,2022,comparedto125.3 million in the same period of 2021[125]. - Capital expenditure commitments as of December 31, 2022, were approximately 23million,primarilyforfacilityexpansionsinPoland,Mexico,andThailand[129].−Anew364−daymulti−currencyrevolvingcreditfacilitywasenteredintoonFebruary3,2023,allowingforborrowingsupto50 million to support equipment and working capital needs[126]. Future Outlook - The EMS industry is projected to grow at a compound annual growth rate (CAGR) of 5.5% through 2026, indicating a favorable market outlook for the company[91]. - The company expects to complete its Poland facility expansion in early fiscal year 2024, following recent expansions in Thailand and Mexico[128]. Shareholder Returns - The company has a Board-authorized stock repurchase plan allowing for the repurchase of up to 100millionofcommonstock,with88.8 million repurchased through December 31, 2022[132].